PPAT

Summary

PPAT (phosphoribosyl pyrophosphate amidotransferase, HGNC:9238) is a protein-coding gene on chromosome 4q12, encoding Amidophosphoribosyltransferase (Q06203). Catalyzes the formation of phosphoribosylamine from phosphoribosylpyrophosphate (PRPP) and glutamine. It is a selective cancer dependency (DepMap: 52.1% of cell lines).

The protein encoded by this gene is a member of the purine/pyrimidine phosphoribosyltransferase family. It is a regulatory allosteric enzyme that catalyzes the first step of de novo purine nucleotide biosythetic pathway. This gene and PAICS/AIRC gene, a bifunctional enzyme catalyzing steps six and seven of this pathway, are located in close proximity on chromosome 4, and divergently transcribed from an intergenic region.

Source: NCBI Gene 5471 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 39 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 52.1% of screened cell lines
• MANE Select transcript: NM_002703

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9238
Approved symbol	PPAT
Name	phosphoribosyl pyrophosphate amidotransferase
Location	4q12
Locus type	gene with protein product
Status	Approved
Aliases	GPAT, PRAT
Ensembl gene	ENSG00000128059
Ensembl biotype	protein_coding
OMIM	172450
Entrez	5471

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 3 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000264220, ENST00000425339, ENST00000507648, ENST00000507724, ENST00000510643, ENST00000913491, ENST00000965522

RefSeq mRNA: 1 — MANE Select: NM_002703 NM_002703

CCDS: CCDS3505

Canonical transcript exons

ENST00000264220 — 11 exons

Exon	Start	End
ENSE00001032561	56400784	56400911
ENSE00001032575	56401330	56401481
ENSE00001074648	56435350	56435615
ENSE00001074653	56399179	56399400
ENSE00001895738	56393362	56395548
ENSE00003466503	56407650	56407716
ENSE00003481598	56396619	56396739
ENSE00003487288	56403040	56403185
ENSE00003593732	56406495	56406701
ENSE00003634206	56402109	56402181
ENSE00003654105	56403289	56403401

Expression profiles

Bgee: expression breadth ubiquitous, 228 present calls, max score 87.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.7476 / max 156.1556, expressed in 1699 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
52193	6.3447	1569
52191	3.5446	1109
52192	0.8584	512

Top tissues by expression

279 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	87.96	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.95	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.70	gold quality
cortical plate	UBERON:0005343	85.61	gold quality
ganglionic eminence	UBERON:0004023	85.52	gold quality
adrenal tissue	UBERON:0018303	84.15	gold quality
embryo	UBERON:0000922	82.00	gold quality
islet of Langerhans	UBERON:0000006	79.79	gold quality
stromal cell of endometrium	CL:0002255	78.36	gold quality
body of pancreas	UBERON:0001150	78.22	gold quality
calcaneal tendon	UBERON:0003701	77.75	gold quality
pancreas	UBERON:0001264	77.59	gold quality
rectum	UBERON:0001052	77.16	gold quality
right adrenal gland cortex	UBERON:0035827	76.83	gold quality
left adrenal gland	UBERON:0001234	76.75	gold quality
ovary	UBERON:0000992	76.43	gold quality
left adrenal gland cortex	UBERON:0035825	76.42	gold quality
left ovary	UBERON:0002119	76.37	gold quality
right adrenal gland	UBERON:0001233	75.98	gold quality
adrenal gland	UBERON:0002369	75.97	gold quality
right ovary	UBERON:0002118	75.70	gold quality
middle temporal gyrus	UBERON:0002771	75.54	silver quality
prefrontal cortex	UBERON:0000451	75.10	gold quality
cerebellar hemisphere	UBERON:0002245	74.61	gold quality
cingulate cortex	UBERON:0003027	74.60	gold quality
right hemisphere of cerebellum	UBERON:0014890	74.57	gold quality
anterior cingulate cortex	UBERON:0009835	74.50	gold quality
cerebellar cortex	UBERON:0002129	74.48	gold quality
lymph node	UBERON:0000029	74.23	gold quality
secondary oocyte	CL:0000655	74.18	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.36
E-GEOD-99795	no	148.59

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

124 targeting PPAT, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 52.1% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 5)

• purine biosynthetic pathway enzymes PPAT and PAICS, as well as pyruvate kinase activity are increased in lung cancer (PMID:26140362)
• The data indicate that amino acid/nucleotide metabolism-related genes OGDH, PPAT and PCCA acquire somatic mutations in microsatellite instability-high gastric cancers and colorectal cancers and that mutational intratumoral heterogeneity may occur in at least some of these tumors. (PMID:27468871)
• Phosphopantetheine Adenylyltransferase: A promising drug target to combat antibiotic resistance. (PMID:33271445)
• Species-Specific Deamidation of RIG-I Reveals Collaborative Action between Viral and Cellular Deamidases in HSV-1 Lytic Replication. (PMID:33785613)
• SHMT2 promotes the tumorigenesis of renal cell carcinoma by regulating the m6A modification of PPAT. (PMID:35798250)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ppat	ENSDARG00000004517
mus_musculus	Ppat	ENSMUSG00000029246
rattus_norvegicus	Ppat	ENSRNOG00000002128
drosophila_melanogaster	Prat	FBGN0004901
drosophila_melanogaster	Prat2	FBGN0041194

Protein

Protein identifiers

Amidophosphoribosyltransferase — Q06203 (reviewed: Q06203)

Alternative names: Glutamine phosphoribosylpyrophosphate amidotransferase

All UniProt accessions (4): Q06203, A8K4H7, D6RCC8, D6RE15

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the formation of phosphoribosylamine from phosphoribosylpyrophosphate (PRPP) and glutamine.

Subunit / interactions. Homotetramer.

Tissue specificity. Ubiquitously expressed.

Cofactor. Binds 1 Mg(2+) ion per subunit. Binds 1 [4Fe-4S] cluster per subunit.

Pathway. Purine metabolism; IMP biosynthesis via de novo pathway; N(1)-(5-phospho-D-ribosyl)glycinamide from 5-phospho-alpha-D-ribose 1-diphosphate: step 1/2.

Similarity. In the C-terminal section; belongs to the purine/pyrimidine phosphoribosyltransferase family.

RefSeq proteins (1): NP_002694* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000836	PRTase_dom	Domain
IPR005854	PurF	Family
IPR017932	GATase_2_dom	Domain
IPR029055	Ntn_hydrolases_N	Homologous_superfamily
IPR029057	PRTase-like	Homologous_superfamily
IPR035584	PurF_N	Domain

Pfam: PF00156, PF13522

Enzyme classification (BRENDA):

• EC 2.4.2.14 — amidophosphoribosyltransferase (BRENDA: 22 organisms, 39 substrates, 103 inhibitors, 55 Km, 3 kcat entries)
• EC 2.7.7.3 — pantetheine-phosphate adenylyltransferase (BRENDA: 25 organisms, 18 substrates, 81 inhibitors, 22 Km, 4 kcat entries)

Substrate kinetics (BRENDA)

13 substrates with measured Km, best-characterized 13. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
L-GLUTAMINE	0.1–236	26
5-PHOSPHO-ALPHA-D-RIBOSE 1-DIPHOSPHATE	0.031–0.87	15
ATP	0.1157–1	6
3’-DEPHOSPHO-COA	0.0067–0.0147	4
DIPHOSPHATE	0.022–0.272	4
PANTETHEINE 4’-PHOSPHATE	0.015–0.19	4
NH3	7.34–16	3
GLUTAMINE	193	1
MG2+	0.65	1
NH4+	16	1
DEPHOSPHO-COA	0.017	1
MG-ATP	0.22	1
PHOSPHOPANTETHEINE	0.0047	1

Catalyzed reactions (Rhea), 1 shown:

• 5-phospho-beta-D-ribosylamine + L-glutamate + diphosphate = 5-phospho-alpha-D-ribose 1-diphosphate + L-glutamine + H2O (RHEA:14905)

UniProt features (13 total): binding site 7, propeptide 1, chain 1, modified residue 1, sequence conflict 1, domain 1, active site 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
9Q0N	ELECTRON MICROSCOPY	2.8
9Q0O	ELECTRON MICROSCOPY	2.9
9Q0M	ELECTRON MICROSCOPY	3.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q06203-F1	86.66	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 12 (nucleophile)

Ligand- & substrate-binding residues (7): 506; 280; 327; 389; 390; 426; 503

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-73817	Purine ribonucleoside monophosphate biosynthesis

MSigDB gene sets: 236 (showing top): RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, MITSIADES_RESPONSE_TO_APLIDIN_DN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, KANNAN_TP53_TARGETS_DN, GOBP_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS, BROWNE_HCMV_INFECTION_12HR_UP, USF_C, CAGCTG_AP4_Q5, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, WEI_MYCN_TARGETS_WITH_E_BOX

GO Biological Process (6): purine nucleotide biosynthetic process (GO:0006164), GMP biosynthetic process (GO:0006177), ‘de novo’ IMP biosynthetic process (GO:0006189), purine nucleobase biosynthetic process (GO:0009113), ‘de novo’ AMP biosynthetic process (GO:0044208), ‘de novo’ XMP biosynthetic process (GO:0097294)

GO Molecular Function (8): amidophosphoribosyltransferase activity (GO:0004044), metal ion binding (GO:0046872), 4 iron, 4 sulfur cluster binding (GO:0051539), catalytic activity (GO:0003824), protein binding (GO:0005515), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757), iron-sulfur cluster binding (GO:0051536)

GO Cellular Component (1): cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Nucleotide biosynthesis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
purine-containing compound biosynthetic process	2
purine nucleotide metabolic process	1
nucleotide biosynthetic process	1
purine ribonucleotide biosynthetic process	1
purine ribonucleoside monophosphate biosynthetic process	1
GMP metabolic process	1
IMP biosynthetic process	1
purine nucleobase metabolic process	1
nucleobase biosynthetic process	1
AMP biosynthetic process	1
XMP biosynthetic process	1
pentosyltransferase activity	1
cation binding	1
iron-sulfur cluster binding	1
molecular_function	1
binding	1
catalytic activity	1
transferase activity	1
metal cluster binding	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2548 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPAT	PAICS	P22234	986
PPAT	PFAS	O15067	983
PPAT	GART	P22102	978
PPAT	ADSL	P30566	910
PPAT	CAD	P27708	805
PPAT	ATIC	P31939	762
PPAT	GMPS	P49915	759
PPAT	PGM2	Q96G03	729
PPAT	APRT	P07741	717
PPAT	ADSS2	P30520	688
PPAT	IMPDH1	P20839	667
PPAT	IMPDH2	P12268	665
PPAT	ADSS1	Q8N142	665
PPAT	MTHFD1	P11586	664
PPAT	PRPS1	P09329	649
PPAT	PRPS2	P11908	649

IntAct

35 interactions, top by confidence:

A	B	Type	Score
MMS19	ERCC2	psi-mi:“MI:0914”(association)	0.690
PPAT	NUDT5	psi-mi:“MI:0915”(physical association)	0.640
B2M	NEMP1	psi-mi:“MI:0914”(association)	0.640
B2M	KPNA3	psi-mi:“MI:0914”(association)	0.530
MAD2L1	PPIP5K2	psi-mi:“MI:0914”(association)	0.530
PPAT	SELENOI	psi-mi:“MI:0915”(physical association)	0.370
ATXN1	PPAT	psi-mi:“MI:0915”(physical association)	0.370
OTUB1	EPM2A	psi-mi:“MI:0914”(association)	0.350
CIAO2B	ELP1	psi-mi:“MI:0914”(association)	0.350
LRRK2		psi-mi:“MI:0914”(association)	0.350
incF	PMPCB	psi-mi:“MI:0914”(association)	0.350
ZDHHC5	IGKV2D-24	psi-mi:“MI:0914”(association)	0.350
HLA-A	AIP	psi-mi:“MI:0914”(association)	0.350
NUDT5	FLNB	psi-mi:“MI:0914”(association)	0.350
CA10	ENTPD5	psi-mi:“MI:0914”(association)	0.350
DNAJA2	ENC1	psi-mi:“MI:0914”(association)	0.350
DNAJC30	UBA6	psi-mi:“MI:0914”(association)	0.350
FAM167A	VWA8	psi-mi:“MI:0914”(association)	0.350
GAB2	UBA6	psi-mi:“MI:0914”(association)	0.350
ITM2C	UBA6	psi-mi:“MI:0914”(association)	0.350
MRPL49	UBA6	psi-mi:“MI:0914”(association)	0.350
PCDHGA9	UBA6	psi-mi:“MI:0914”(association)	0.350
PEX7	UBA6	psi-mi:“MI:0914”(association)	0.350
VENTX	UBA6	psi-mi:“MI:0914”(association)	0.350
CFTR	UBA6	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (92): PPAT (Affinity Capture-MS), G6PD (Affinity Capture-MS), CCZ1 (Affinity Capture-MS), HDAC3 (Affinity Capture-MS), PPAT (Affinity Capture-MS), ARHGAP1 (Co-fractionation), GART (Co-fractionation), IMPDH2 (Co-fractionation), NPEPL1 (Co-fractionation), PAK1 (Co-fractionation), PPAT (Co-fractionation), PPAT (Co-fractionation), PPAT (Co-fractionation), PPAT (Co-fractionation), PRPS1 (Co-fractionation)

ESM2 similar proteins: A0A3L7I2I8, A0FKG7, A1Z6E0, A6QLT2, A8QGZ7, B0X9V1, B3MDR0, B3NRP1, B4F739, B4GBN7, B4HQ29, B4J6Q0, B4KNC5, B4LMQ3, B4MR59, B4P4K8, B4QE02, O60733, P0C2W1, P0CH38, P23727, P27986, P28173, P33121, P35433, P37287, P41216, P53041, P53042, P97570, P97819, Q06203, Q13614, Q16XV7, Q27601, Q290L5, Q5R685, Q5REB9, Q60676, Q6NZ03

Diamond homologs: A0A7T8J1U7, O26273, O26742, O29388, O57979, P00497, P04046, P0AG16, P0AG17, P28173, P35433, P35853, P41390, P43854, P52418, P52419, P65830, P65831, P77935, P99164, P9WHQ6, P9WHQ7, Q06203, Q12698, Q27601, Q50028, Q51342, Q55038, Q55621, Q57657, Q577Y1, Q5FUY5, Q5HH14, Q5HQA0, Q6GAE3, Q6GI14, Q86A85, Q8CIH9, Q8CT30, Q8CY30

SIGNOR signaling

8 interactions.

A	Effect	B	Mechanism
PPAT	“down-regulates quantity”	“L-glutamine zwitterion”	“chemical modification”
PPAT	“up-regulates activity”	Purine_biosynthesis
PPAT	“up-regulates quantity”	5-phospho-beta-D-ribosylaminium(1-)	“chemical modification”
PPAT	“down-regulates quantity”	“5-phospho-α-D-ribose 1-diphosphate”	“chemical modification”
PPAT	“up-regulates quantity”	L-glutamate(1-)	“chemical modification”
NFE2L2	“up-regulates quantity by expression”	PPAT	“transcriptional regulation”
MYC	“up-regulates quantity by expression”	PPAT	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

39 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	25
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

3358 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:56399246:T:A	D390V	1.000
4:56399344:G:C	F357L	1.000
4:56399344:G:T	F357L	1.000
4:56399346:A:G	F357L	1.000
4:56435431:C:T	G16E	1.000
4:56396663:A:G	L438P	0.999
4:56396691:C:G	G429R	0.999
4:56396691:C:T	G429R	0.999
4:56396698:G:C	C426W	0.999
4:56396700:A:G	C426R	0.999
4:56399244:A:G	S391P	0.999
4:56399245:A:C	D390E	0.999
4:56399245:A:T	D390E	0.999
4:56399246:T:C	D390G	0.999
4:56399246:T:G	D390A	0.999
4:56399247:C:G	D390H	0.999
4:56399345:A:C	F357C	0.999
4:56399345:A:G	F357S	0.999
4:56399350:T:A	R355S	0.999
4:56399350:T:G	R355S	0.999
4:56399351:C:A	R355I	0.999
4:56399351:C:G	R355T	0.999
4:56400832:G:C	S322R	0.999
4:56400832:G:T	S322R	0.999
4:56400834:T:G	S322R	0.999
4:56403108:C:G	R198P	0.999
4:56403360:A:C	S148R	0.999
4:56403360:A:T	S148R	0.999
4:56403362:T:G	S148R	0.999
4:56406529:C:A	G123V	0.999

dbSNP variants (sampled 300 via entrez): RS10000147 (4:56394795 A>G), RS1000028114 (4:56434461 C>T), RS1000127698 (4:56414252 T>C), RS1000293847 (4:56406192 G>A), RS1000386892 (4:56420672 G>A,C), RS1000389708 (4:56413788 T>C), RS1000466178 (4:56416025 A>G,T), RS1000548492 (4:56399664 A>T), RS1000549232 (4:56434737 T>C), RS1000669384 (4:56422405 C>T), RS1000735527 (4:56420982 T>G), RS1000774872 (4:56415235 A>G), RS1001017892 (4:56426319 T>C), RS1001029821 (4:56408091 T>A), RS1001069837 (4:56426591 C>T)

Disease associations

OMIM: gene MIM:172450 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2362992 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — C44: Phosphoribosyl pyrophosphate amidotransferase

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tetrachlorodibenzodioxin	decreases expression	3
sodium arsenite	increases expression, decreases expression, increases abundance	2
Arsenic	increases methylation, increases abundance, increases expression	2
Tretinoin	decreases expression	2
Cadmium Chloride	decreases reaction, increases abundance, increases palmitoylation, decreases expression	2
aristolochic acid I	increases expression, decreases expression	1
TAK-243	increases sumoylation	1
alpha phellandrene	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
bisphenol A	decreases expression	1
cobaltous chloride	decreases expression	1
2-bromopalmitate	decreases reaction, increases abundance, increases palmitoylation	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
beta-methylcholine	affects expression	1
pinosylvin	decreases expression	1
tamibarotene	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
abrine	decreases expression	1
jinfukang	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Dasatinib	affects binding	1
Resveratrol	affects cotreatment, increases expression	1
Arsenic Trioxide	increases expression	1
Acetaminophen	increases expression	1
Biological Factors	decreases expression	1
Cadmium	increases palmitoylation, decreases reaction, increases abundance	1
Carbamazepine	affects expression	1
Copper	affects cotreatment, increases expression	1
Coumestrol	affects cotreatment, increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118787	Binding	Binding affinity to PPAT in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.